Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Other Accumulated Expenses (2019 - 2025)

BioNexus Gene Lab's Other Accumulated Expenses history spans 7 years, with the latest figure at $56803.0 for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 17.81% year-over-year to $56803.0; the TTM value through Sep 2025 reached $56803.0, up 17.81%, while the annual FY2024 figure was $50816.0, 46.73% up from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $56803.0 at BioNexus Gene Lab, up from $55809.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $56803.0 in Q3 2025 and bottomed at -$16793.0 in Q1 2021.
  • The 5-year median for Other Accumulated Expenses is $18566.0 (2021), against an average of $28853.0.
  • The largest annual shift saw Other Accumulated Expenses surged 266.48% in 2021 before it tumbled 36.54% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $18272.0 in 2021, then fell by 9.32% to $16569.0 in 2022, then surged by 109.02% to $34632.0 in 2023, then skyrocketed by 46.73% to $50816.0 in 2024, then grew by 11.78% to $56803.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Other Accumulated Expenses are $56803.0 (Q3 2025), $55809.0 (Q2 2025), and $52173.0 (Q1 2025).